Originally published In Press as doi:10.1074/jbc.M200752200 on March 23, 2002
J. Biol. Chem., Vol. 277, Issue 23, 20651-20659, June 7, 2002
The Role of Region IVS5 of the Human Cardiac Calcium
Channel in Establishing Inactivated Channel Conformation
USE-DEPENDENT BLOCK BY BENZOTHIAZEPINES*
Ilona
Bodi
§,
Sheryl E.
Koch
,
Hiroshi
Yamaguchi
,
Gyula P.
Szigeti¶,
Arnold
Schwartz
, and
Gyula
Varadi
From the
Institute of Molecular Pharmacology and
Biophysics, the Department of Surgery, University of Cincinnati College
of Medicine, Cincinnati, Ohio 45267-0828 and the ¶ Department of
Physiology and Biophysics, School of Medicine and Biomedical Sciences,
State University of New York, Buffalo, New York 14214
Received for publication, January 23, 2002, and in revised form, March 18, 2002
 |
ABSTRACT |
The role of inactivated channel conformation and
use dependence for diltiazem, a specific benzothiazepine calcium
channel inhibitor, was studied in chimeric constructs and point mutants created in the IVS5 transmembrane segment of the L-type cardiac calcium
channel. All mutations, chimeric or point mutations, were restricted to
IVS5, while the YAI-containing segment in IVS6, i.e. the
primary interaction site with benzothiazepines, remained intact. Slowed
inactivation rate and incomplete steady state inactivation, a behavior
of some mutants, were accompanied by a reduced or by a complete loss of
use-dependent block by diltiazem. Single channel properties
of mutants that lost use dependence toward diltiazem were characterized
by drastically elongated mean open times and distinctly slower time
constants of open time distribution. Mutation of individual residues of
the IVMLF segment in IVS5 did not mimic the complete loss of use
dependence as observed for the replacement of the whole stretch. These
results establish evidence that amino acids that govern inactivation
and the drug-binding site and other amino acids that are located distal
from the putative drug-binding site contribute significantly to the
function of the benzothiazepine receptor region. The data are
consistent with a complex "pocket" conformation that is responsive
to a specific class of L-type calcium channel inhibitors. The data
allow for a concept that multiple sites within regions of the
1 subunit contribute to auto-regulation of the L-type
Ca2+ channel.
 |
INTRODUCTION |
L-type Ca2+ channels of cardiac, skeletal, and smooth
muscle play a central role in excitation-contraction coupling.
It is also believed that these channels may participate in the
pathophysiology of some cardiac arrhythmias, hypertension, and angina
pectoris (1-4). Increases in [Ca2+]i have been
linked to a variety of changes in membrane properties that contribute
to the changes in excitability, conduction, refractoriness,
automaticity, and vascular resistance (1-4). In terms of
excitation-contraction coupling, Ca2+ enters the cell
during depolarization through voltage-activated calcium channels and
triggers contraction but also is responsible for activation of other
cellular functions. In the course of sustained depolarization,
Ca2+ currents progressively undergo
voltage-dependent inactivation with specific kinetics,
primarily regulated by the membrane potential.
Ca2+ channels are the target for three main classes of
drugs that include dihydropyridines
(DHP),1 phenylalkylamines
(PAA), and benzothiazepines (BTZ). These molecules bind specifically to
different sites of the Ca2+ channel
1
subunit, and their binding domains are allosterically linked to each
other (5-7). Ca2+ channel antagonists, particularly
diltiazem and verapamil, block calcium channels in a voltage- and
use-dependent manner; thus the binding of the drug
facilitates protein conformational changes that alter channel function
by interfering with channel gating. These drugs serve as useful tools
in dissecting molecular mechanisms of channel inactivation. Several
amino acid residues that are involved in Ca2+ antagonist
binding, when mutated, change the electrophysiological properties of
the channel, such as voltage-dependent inactivation. Single
amino acids in segments IIIS6 and IVS6 (5, 8-11) have been identified
as determinants of inactivation. Mutation of key amino acids in these
segments alters not only the high affinity drug-binding sites but also
the complexity of the kinetic behavior of the channels, consequently
changing use-dependent block particularly for the PAAs and
BTZs (for review, see Ref. 12).
Our previous finding showed that a segment in IVS5 of the human
1C (Cav1.2) subunit is critically involved
in inactivation of the channel (13). Consequently, mutants constructed
in this region lost the characteristic use-dependent block
by PAA and BTZ and recovered from inactivation significantly faster
after drug block compared with the wild type channel. However,
[3H]PN200-110 (isradipine) binding and allosteric
interaction assays revealed that the DHP and BTZ receptor sites
maintained normal coupling in the chimeric mutant channels. In the
present study, we analyze the impact of individual amino acids in IVS5
(Ile, Val, Met, Leu, Phe) on the inactivation of the human
1C subunit. Our observations with point mutants in IVS5
strongly suggest that amino acid substitutions outside of or distal to
the IIIS6 and IVS6 segments, where the key positions for drug
interactions are located, play a critical ancillary role in determining
inactivation kinetics and use dependence of the channel.
 |
EXPERIMENTAL PROCEDURES |
Site-directed Mutagenesis of Human Heart
1C--
Amino acids that reside in the IVS5 region of
human heart
1C (Ile, Val, Met, Leu, Phe) were
sequentially mutagenized. A two-step PCR method, termed
"megaprimer" PCR was utilized. The first set of
oligonucleotides (forward primers) carrying the desired bases had at least 15 nucleotides on either side of the mutation and had the
sequence GTG GCC CTC CTG ATC TTC ATG CTG TTC TTC ATC; CTC
CTG ATC GTG ATG GTG TTC TTC ATC TAC GCG; CTG ATC GTG ATG
CTG ATG TTC ATC TAC GCG GTG; CCC TAT GTG GCC CTC CTG CTC
TTC CTG GTG TTC TTC ATC TAC GCG for V1339F, L1341V, F1342M,
and HHT-5421, respectively. The reverse primer GGT TGA TGA TCA GGA AGG
C was designed around the BclI site (4311) of hHT-1 (14).
PCR was performed on the hHT-1 template using in each reaction one
mutant primer and a BclI primer. The amplification products
(526 bp) were isolated from high range agarose gel.
After purification, these products were utilized as megaprimers, and
PCR amplifications were done between a primer designed around the
AatII site (3807) and the individual megaprimers. The products were gel-isolated again and ligated into the EcoRV
site of pBlueScript KS (
), and DNA from a number of resultant clones was sequenced to identify correct mutant cDNAs. Finally, the
mutant cassettes were liberated by AatII and BclI
restriction cleavage, isolated, and ligated into
AatII/BclI-cleaved hHT-1 to replace the
corresponding wild type segment of
1C.
Expression of Calcium Channels in Xenopus
Oocytes--
Expression of the wild type and mutant calcium channels
was done as previously described (15). In vitro synthesized
cRNA was made using the mMessage mMachine synthesis kit (Ambion).
Xenopus oocyte isolation and cRNA injection were performed
as published elsewhere (16). Briefly, female Xenopus
laevis (purchased from Xenopus I, Ann Arbor, MI)
frogs were anesthetized by exposing them for 15-20 min to 0.15%
methanesulfonate salt of 3-aminobenzoic acid ethyl ester (MS-222;
Sigma) solution before pieces of the ovary were removed. The follicular
layers of the oocytes were digested with 2.0 mg/ml collagenase (Type
IA; Sigma) dissolved in OR-2 medium (in mM): 82.5 NaCl, 1 KCl, 1 MgCl2, and 5 HEPES, pH 7.5. Stage V-VI oocytes were
incubated at 19 °C in P/S medium (in mM): 96 NaCl, 2.0 KCl, 1.0 MgCl2, 1.8 CaCl2, 5 HEPES, 2.5 sodium
pyruvate, and 0.5 theophylline at pH 7.5. The P/S medium was
supplemented with 100 units/ml penicillin and 100 µg/ml streptomycin.
The wild type and mutant
1C (14) messages were
co-injected in a 50-nl solution composed of
2/
(2,
17) and human
3 (15, 18) subunits in a 2:1:1 molar
ratio. Ca2+ channel currents were recorded 2-4 days
postinjection of the cRNAs at room temperature (20-21 °C). To
minimize contamination with chloride current, oocytes were
microinjected with 50 nl of a 40 mM K4-BAPTA
solution (potassium
1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetate in 10 mM HEPES, pH 7.05) 60 min prior to current recording.
Whole cell currents were recorded using the standard two-microelectrode voltage-clamp technique.
Whole-cell Ba2+ Current Recordings--
The
recording medium was a Ca2+- and Cl
-free
solution composed of (in mM): 40 Ba(OH)2, 50 N-methyl-D-glucamine, 2 KOH, 5 HEPES, pH
adjusted to 7.4, with methanesulfonic acid. Voltage and current electrodes were filled with 3 M KCl and had a resistance of
0.5-1.5 megohms. Currents were recorded using an Axoclamp-2A (Axon
Instruments Inc., Foster City, CA) amplifier. Whole cell leakage and
capacitive currents were subtracted on line using the P/4 procedure
(19). Currents were digitized at 1 kHz after being filtered at 1 kHz. The pClamp software (version 5.6 Axon Instruments) was used for data
acquisition, and version 6.0.3 was used for analysis.
Ba2+ currents were elicited by a 350-ms-long
depolarizing pulse from a holding potential of
80 mV to test
potentials between
30 mV and +40 mV in 10-mV increments to determine
the peak potentials of the current voltage relationship of the
Ca2+ channel construct.
Use-dependent block was determined as the inhibition of
peak IBa during trains of 15 test pulses of 80-ms duration
applied at 0.5 Hz from a holding potential of
60 mV to test
potentials +20 mV positive to the peak potential of the I-V curves.
Identical pulse protocols were used in the presence of drugs. Diltiazem (racemic) was perfused in the bath (for a 2.5-min period) at
concentrations of 200 µM. This concentration was selected
because it provided sufficient block for the use-dependent
measurements in Xenopus oocytes (13).
A double pulse protocol was used in those experiments measuring the
voltage dependence of steady-state inactivation. The protocol consisted
of a 5-s prepulse that ranged from
80 to +50 mV at a holding
potential of
80 mV followed by a 30-ms return pulse to
80 mV.
Finally a 400-ms-long test pulse was applied at +20 mV. The curves were
fit to the Boltzmann equation y = A1
A2/(1 + exp
(x
x0)/dx)*
A2.
Recovery from Inactivation--
Recovery of IBa from
inactivation was studied after depolarizing the calcium channels during
a 3-s prepulse to +20 mV. The time course of IBa recovery
from inactivation was estimated at a holding protential of
80
mV by applying a 400-ms test pulse to +20 mV at various time intervals
after the conditioning prepulse. Peak IBa values were
normalized to the peak current amplitude measured during the prepulse.
After the double-pulse protocol, the membrane was hyperpolarized to
100 mV for 3 min to permit complete recovery from inactivation and block.
Single Channel Recordings--
Single channel recordings were
obtained from cell-attached patches using an AXON 200 amplifier (20).
After mechanically removing the vitelline membrane of
Xenopus oocytes (after about 5 min of incubation in
hypertonic solution composed of in mM: 200 potassium-aspartate, 20 KCl, 1.0 MgCl2, 10 EGTA, 10 HEPES), the membrane potential of the oocytes was "zeroed" with a high potassium medium composed of (in mM): 140 KCl, 2 MgCl2, 5 EGTA, and 5 HEPES, pH 7.4. The patch electrodes
were coated with Sylgard, then fire-polished, and had resistances
between 5 and 20 megohms. The pipette solution contained (in
mM): 110 BaCl2 and 10 HEPES, pH 7.4. Single
channel currents were low pass-filtered at 2 kHz, digitized at 10 kHz,
and stored for off-line analysis. Only well resolved openings were
measured; therefore, all single channel experiments were conducted in
the presence of 1 µM Bay K8644 at room temperature
(22-23 °C). To cancel capacitive transients and leak currents,
blank records with no openings were subtracted from those with
openings. Patch potentials were maintained at
80 mV, and 500 depolarizing pulses (180 ms long) to +20, +30, and +40 mV,
respectively, were delivered. Open and closed transitions were detected
by the half-amplitude threshold criterion. Open time histograms were
fitted to multiple exponential functions by using the maximum
likelihood method. Analysis was performed on 3-10 patches in which we
succeeded in recording from 500 up to 1000 sweeps.
 |
RESULTS |
To examine the role of individual amino acid residues in
governing the participation of transmembrane segment IVS5 in
inactivation and use-dependent block, we substituted each
amino acid of the wild type
1 in the region where
previously we identified a segment with a chimeric construct (HHT-5411)
that is a determinant of inactivation (Fig.
1). By analyzing the macroscopic
Ba2+ currents, we noticed in mutants I1338L and M1340L that
the half-maximal voltage for activation (V0.5 act) was
slightly but significantly shifted to negative potentials (Table
I). The reversal potential (data not
shown), and peak potential (data not shown), were not significantly
affected by any of the mutations. There was, however, a slight but
significant change in the slope factor
(kact) for I1338L, M1340L, and
HHT-5421 (Table I).

View larger version (45K):
[in this window]
[in a new window]
|
Fig. 1.
A schematic of
1C IVS5 transmembrane segment. The
region replaced in chimeric constructs is boxed.
|
|
View this table:
[in this window]
[in a new window]
|
Table I
Activation and inactivation parameters of wild type and mutant calcium
channels
The voltage dependence of activation was determined from I-V curves
obtained by step depolarizations from a holding potential 80 mV to
various test potentials. To obtain the voltage of half-maximal
IBa activation (V0.5 act) current-voltage relation
curves were fitted to the Boltzmann function. kact
is the slope factor of the activation curve. The voltage dependence of
inactivation (steady-state inactivation) was investigated for WT and
mutant channels in control and in the presence of 200 µM
diltiazem. The half-maximal voltage for steady state inactivation
(V0.5 inact) and the slope factor (kinact)
were calculated by fitting the data to the Boltzmann equation. The
inactivation rates for Vm = +20 mV were estimated from a single
trace at time t = 3 s. The inactivation time
course of whole cell Ba2+ traces was determined by a double
exponential fitting. The p values (<0.05) for comparison to
the wild type channels are marked as * next to each
electrophysiological value.
|
|
On the other hand, we observed more widespread alterations in the
inactivation properties of mutants. The V0.5 act of the
steady-state inactivation drastically shifted to hyperpolarized potentials for L1341V and the HHT-5421 chimera. Also, the inactivation rate was significantly slower for L1341V, F1342M, and the HHT-5421 compared with the wild type.
Ca2+ Channel Block by Diltiazem Determined by Amino
Acids in IVS5--
In the next set of experiments, we tested whether
the alterations in inactivation properties of certain mutant channels
correlated with the use dependence properties. Indeed, the reduced rate
in current inactivation of HHT-5421 and L1341V was accompanied by a
substantial reduction in use-dependent block of
IBa by diltiazem during 80-ms steps at 0.5 Hz. On the
contrary, mutation V1339F enhanced use-dependent block by
diltiazem (and also by verapamil, data not shown) during low frequency
pulse trains compared with wild type (WT) channel. The single
phenylalanine to methionine substitution (F1342M) and the other two
mutants, M1340L and I1338L in segment IVS5 of
1, induced
similar use-dependent IBa inhibition by
diltiazem compared with the wild type (Fig.
2, B and C).

View larger version (26K):
[in this window]
[in a new window]
|
Fig. 2.
Contribution of individual amino acids in
transmembrane segment IVS5 for BTZ sensitivity.
Use-dependent IBa inhibition during trains of
15 consecutive depolarizing voltage steps applied at 0.5 Hz in the
absence (A) and presence (B) of 200 µM diltiazem. Use-dependent block of wild
type and mutant L-type Ca2+ channel currents in the
presence of 200 µM diltiazem (open) compared
with peak current decay in control (filled). a 0.5-Hz train
consisting of fifteen 80-ms depolarizations from 60 to +20 mV was
applied. IBa amplitudes were normalized to the amplitude of
IBa elicited by the first pulse in a train. The relative
reduction in peak current is plotted against pulse number
(C).
|
|
Interrelationship between Channel Inactivation and Block
Development by Diltiazem--
The voltage dependence of steady-state
inactivation, induced by a 5-s prepulse, showed that WT, I1338L,
V1339F, M1340L, and F1342M mutant channels are nearly completely
inactivated at positive voltages (Table I). In contrast, the
steady-state inactivation curves for HHT-5421 and L1341V exhibited a
slowed rate of inactivation and also a residual current that appears
associated with a loss of voltage dependence. The half-maximal voltage
for inactivation (V0.5 inact) was shifted toward more
positive potentials for mutant HHT-5421 (
0.4 ± 1.7 mV) and for
L1341V (2.4 ± 4.9 mV) compared with that of the wild type channel
(
7.6 ± 1.8 mV). The slope factor of the curve was not
significantly affected for L1341V (11.0 ± 0.7 mV), but a change
occurred for HHT-5421 (7.1 ± 0.3 mV) compared with the WT
(11.9 ± 0.5 mV) (Fig.
3A). These latter two mutant
channels inactivated completely after diltiazem addition, and no
sustained current remained at the end of the depolarizing pulse (Fig.
3B). This observation indicates that the transition between
the open state and inactivated state and/or the stability of the
inactivated state are impaired by these mutations.

View larger version (32K):
[in this window]
[in a new window]
|
Fig. 3.
Voltage-dependent inactivation
and the recovery of IBa from inactivation for single amino
acid mutants and chimeric constructs within transmembrane segment
IVS5. A, steady-state inactivation curves are shown for
wild type, I1338L, V1339F, M1340L, L1341V, F1342M, and HHT-5421 in the
absence of drug. Currents were elicited by test pulses to +20 mV
following 5-s conditioning pulses to various potentials from a holding
potential of 80 mV. Voltage dependence of inactivation of
1C wild type and mutants coexpressed with
2a and 2/ subunits is shown in
A, in which normalized peak current during test pulse is
plotted as a function of conditioning prepulse. Experimental points
were fitted by a Boltzmann distribution. IBa = 1/{1+exp
[(V V0.5)/k]}, where
V0.5 is the voltage at half-maximum of inactivation, and
k is a slope factor. B, effects of wild type and
mutants, L1341V and HHT-5421, on the voltage dependence of inactivation
in the presence of 200 µM diltiazem. C,
recovery from inactivation of wild type, I1338L, V1339F, M1340, L1341V,
F1342M, and HHT-5421 were measured by a two-pulse protocol in the
absence of diltiazem. The currents were inactivated by a 3-s prepulse
to +20 mV. IBa recovery at 80 mV was measured by applying
a sequence of test pulses at various times after the prepulse. Peak
currents of the test pulses were normalized to peak currents of the
prepulse and against time. Plotted lines represent fits of the mean
data by single exponentials. D, recovery of IBa
from inactivation in the presence of 200 µM diltiazem of
wild type, L1341V, and HHT-5421 mutant channels.
|
|
The accumulation of channels in inactivation during a pulse train
depends on how fast inactivation is removed between pulses. To provide
a more detailed analysis of the role of channel inactivation in block
development, we investigated the effects of the mutations on the time
course of recovery from inactivation by employing a double pulse
protocol at a holding potential
80 mV (Fig. 3C). In
general, IBa recovered to 80-90% of control within
28 s, whereas the remaining current did not recover within the
28-s period analyzed. The effect of diltiazem appeared in an overall
slowing of the recovery time course in the WT and mutant channels. The
recovery time courses in the absence of drug were similar for the WT
(
1 = 1655.3 ± 172.9 ms, n = 8) and
mutant channels, I1338L, M1340L, and F1342M (see Table
II), while HHT-5421 (
1 = 541.6 ± 180.2 ms, n = 3) and L1341V
(
1 = 782.5 ± 231.9 ms, n = 8)
recovered with a faster time course. The recovery of V1339F followed a
slower time course than the WT when approximated with a single
exponential. The tendency remained similar in the presence of diltiazem
(Table II). Approximating the recovery by two exponentials gave more insight into the biphasic nature of the procedure. None of the mutations showed significant differences compared with the WT in the
early faster pulse (
1) of the recovery from inactivation when tested in the absence of drug. However, in the absence of drug,
mutation V1339F recovered according to a slower
2, while L1341V showed a
2 faster than WT in the slow phase of
recovery. This is in good agreement with that observed for the single
exponential approximation. Addition of diltiazem drastically slowed the
fast phase of recovery from inactivation for WT (
fast = 1531.2 ± 179.8 ms versus 70.4 ± 14.2 ms) and had
a smaller, yet noticeable effect (5294.4 ± 673.4 ms
versus 2066.1 ± 103.2 ms) on the slow phase of
recovery. Mutants I1338L, V1339F, M1340L, L1341M, F1342M, and HHT-5421
recovered significantly faster than wild type in the fast phase (see
Table II); however, this behavior was observed only for L1341V and
HHT-5421 in the slow phase of recovery (Fig. 3D).
View this table:
[in this window]
[in a new window]
|
Table II
Time constants of recovery from inactivation for wild type and mutants
I1338L, V1339F, M1340L, L1341V, F1342M, and HHT-5421 in the absence and
presence of 200 µM diltiazem
*, p < 0.05. ND, not determined.
|
|
Single Channel Behavior of IVS5 Mutants--
If mutant channels
enter the inactivated state from the open state more slowly than the
wild type one can assume that these channels will display an increased
mean open time compared with the wild type. To obtain further insight
into the mechanism as to how the impaired inactivation is established
in certain mutants, six of the IVS5 mutants and the wild type channel
were analyzed for single channel properties as outlined under
"Experimental Procedures." Single channel recordings were performed
in the cell-attached configuration mode with 110 mM
Ba2+ in the pipette and in the presence of 1 µM Bay K8644 in the recording bath solution.
Representative traces of single channel recordings for five mutants and
the wild type are depicted in Fig. 4,
left. Open time distribution for wild type, V1339F, L1341V,
HHT-5371, HHT-5411, HHT-5421 (Fig. 4, right), and F1342M
(not shown) were optimally fit with two exponentials (20-22) when
modified with the DHP agonist, Bay K8644. Both fast and slow time
constants for the open time distribution were slower for the chimeric
mutant HHT-5411 (
fast = 2.70 ± 1.02 ms,
slow = 11.18 ± 1.49 ms) and HHT-5421
(
fast = 1.56 ± 0.29 ms,
slow = 14.92 ± 2.24 ms) at +30 mV compared with WT (
fast = 1.33 ± 0.09 ms,
slow = 5.19 ± 0.49 ms).
Surprisingly, the mean open time constants for chimeric mutant HHT-5371
at +30 mV were faster (
fast = 1.05 ± 0.39 ms,
slow = 3.56 ± 0.74 ms) than WT
(
fast = 1.33 ± 0.09 ms,
slow = 5.19 ± 0.49 ms); however, this channel had a high frequency of
short re-openings throughout the depolarizing pulse. Despite the
decreased use-dependent block (Fig. 2), the mean open time for HHT-5371 was also shorter at both +20- and +30-mV depolarizing pulses compared with the WT (Fig.
5A, Table
III). Interestingly, when valine was
replaced with the more hydrophobic phenylalanine in mutant V1339F, the
open time constants were shortened compared with the WT. This finding
suggests crucial roles for size and hydrophobicity of the residue at
position 1339 for inactivation. The single channel data for V1339F are
supported by an enhanced use dependence and slowed recovery from
inactivation. In contrast, substituting leucine for valine at position
1341 had diverse effects on single channel recordings that were
anticipated from the reduced use-dependent block for
diltiazem. These results are summarized in Table III. The longest open
time was observed for the mutants HHT-5411 (6.45 ± 0.6 ms,
n = 5) and HHT-5421 (11.17 ± 1.33 ms, n = 7), 123 and 261% of the wild type, respectively
(Table III, Fig. 5B). Thus, these mutants exhibited slowed
inactivation from the open state (Fig. 5B). These
observations are also consistent with the data from the inactivation of
macroscopic currents (Table I). The average latencies to the first
opening for all mutants was similar to that of the wild type,
suggesting that these mutations have little effect on the
activation process (Fig. 5C).

View larger version (30K):
[in this window]
[in a new window]
|
Fig. 4.
Selected representative original current
traces of single channel activity recorded from oocytes expressing the
wild type and mutant Ca2+ channels. Currents were
induced by 180-ms-long depolarizations from a holding potential of 80
to +30 mV in the presence of 1 µM Bay K8644.
Representative current traces are shown on the left. Single
channel open times are shown on the right. Corresponding
open time histograms are displayed for wild type, mutant V1339F,
L1341V, HHT-5371, HHT-5411, and HHT-5421.
|
|

View larger version (29K):
[in this window]
[in a new window]
|
Fig. 5.
Parameters obtained from single channel data
using cell-attached patches. Parameters for the channel open time
tested with 500 depolarizing pulses to +20, +30, and +40 mV from a
holding potential of 80 mV are shown. A, mean open time
for each clone. B, fast and slow time constants for double
exponential fitting of open time histograms at +30 mV. C,
averaged latency to first openings measured at the test potentials
indicated. Data are represented as means ± S.E. of four to nine
different patches.
|
|
View this table:
[in this window]
[in a new window]
|
Table III
Parameters of single channel recordings for wild type and mutant
channels
Open time histograms were fitted with a sum of two exponentials.
fast and slow are time constants. f1 and
f2 are the fraction of open time that are contributed by
openings corresponding to fast and slow
respectively. Parameters for the channel open time analyzed with 500 depolarizing pulses to +30 mV. Data are means ± S.E. obtained
from four to nine experiments. * indicates statistically significant
differences from values from the wild type, with p < 0.05.
|
|
 |
DISCUSSION |
We have carried out a systematic analysis of the role of a stretch
of amino acid residues in IVS5 of the human
1C channel in establishing slow, incomplete inactivation and also establishing a
correlation with use-dependent block by diltiazem.
In previous experiments, after expression in Xenopus
oocytes, chimeric mutants HHT-5371 and HHT-5411 (13) decreased
use-dependent block and shifted voltage dependence of
steady-state inactivation to positive membrane potentials, and the
inactivation appeared incomplete. For these mutants, the recovery from
inactivation was accelerated at negative membrane potentials. Here we
have shown that the destabilized inactivation is due both to the
decreased rate of inactivation from the open state and an increased
rate of exit from the inactivated state. The mean open time was
increased for HHT-5421 and HHT-5411 compared with wild type suggesting
a defect in the process of inactivation. Despite the slow inactivation
kinetics of HHT-5371 at the macroscopic level, the mean open time was
not changed compared with that of the wild type channel. Single channel
analysis revealed frequent reopenings for HHT-5371 indicating a
substantial impairment of the stability of the inactivated state.
We attempted to introduce a wild type-like inactivation into HHT-5411
through single amino acid exchanges. We constructed the HHT-5421 mutant
channel by introducing a phenylalanine at position 1340 in HHT-5411,
which is recognized as being important for the inactivation. This
phenomenon is similar to that found in Na+ channels, where
at the corresponding position, a phenylalanine was shown to play an
essential role in fast inactivation (23). Interestingly, the single
amino acid difference from HHT-5411 to HHT-5421 did not exert the
anticipated wild type-like inactivation but showed a more extensive
use-dependent block by diltiazem compared with HHT-5411.
Recent evidence provided further proof (24) that Ile-1485 and Met-1487,
also called an IFM cluster in the Na+ channel,
contribute to stabilizing the hydrophobic inactivation particle for
fast inactivation. In our study, however, because none of the mutations
were introduced in the binding site region, we speculate that mutations
in HHT-5421 and HHT-5411 may cause a conformational modification of the
binding site that slows the formation of the inactivation gate or
decreases the drug access to the binding site of the channel by steric
hindrance. We assume that the cluster of LFLVM and LFLVF amino acids
enters into a hydrophobic interaction with other amino acids in the
intracellular mouth of the pore during the inactivation process. On the
other hand, replacement of valine with a bulkier phenylalanine (V1339F) that has a higher molecular weight than valine enhanced the
use-dependent block, while the inactivation rate remained
similar to that of the wild type. In mutant L1341V, however, we
observed a decreased use-dependent block by diltiazem,
slowed Ca2+ current decay, and facilitated IBa
recovery from inactivation. Leucine and valine are both aliphatic,
hydrophobic amino acids, but valine has a smaller molecular weight and
is less hydrophobic than leucine. However, contrary to previous studies
concentrating on segment IIIS6 in the
1 subunit of
L-type Ca2+ channels (11, 25, 26), our results suggest that
the valine in this position actually destabilizes the inactivated
state. L1341V and HHT-5421 (HHT-5411 and HHT-5371) (13) shifted the voltage dependence of steady-state inactivation to more positive membrane potentials and inactivated incompletely during the pulse, and
a substantial sustained current remained at the end of the depolarization. Therefore, it is possible that these mutant channels might increase the energy requirement from the closed states to the
inactivated state (27). After replacement of phenylalanine by
methionine to create mutant F1342M, we observed a very small effect on
inactivation, which is in accordance with results from previous studies
on the Na+ channel (28). At this point, however, we cannot
confirm that just one critical amino acid is linked to the impaired
inactivation in the IVS5 region and is responsible for channel
gating. In fact, we feel that the importance of the hydrophobic amino
acids, phenylalanine, valine, isoleucine, and leucine, and their
apparent involvement as critical elements for gating, are
evident. It is also possible that four or five amino acids in the IVS5
of the human
1C subunit segment represent a domain that
is critical for the faster inactivation. Among the six new mutants
investigated, mutants HHT-5421 and L1341V caused the most pronounced
effect on channel inactivation kinetics as well as diltiazem
sensitivity. The effect of the HHT-5421, HHT-5411, and L1341V
mutations, i.e. slow entry into the inactivated state,
implies that these amino acid residues participate in a conformational
change that may be required to form an effective inactivation gate receptor.
Taken together, our results provide convincing evidence that IVMLF
mutations in the IVS5 segment affect overall
1C
Ca2+ channel inactivation kinetics compared with wild type.
Previous findings described changes in the inactivation properties by
site-directed mutations in the IVS6 and IIIS6 segments in the pore
region, in the binding motifs, or near the binding pocket of
voltage-gated Ca2+ channels. Numerous previous studies
focused on inactivation determinants in segment IVS6 and IIIS6 that
participate in the formation of the binding pocket for PAA and BTZ
(12). In 1995, Hockermann et al. (29) identified
three pore-oriented amino acid residues in IVS6 (Tyr-1463, Ala-1467,
and Ile-1470) as critical determinants for high affinity block by PAA.
Later, Johnson et al. (30) analyzed the pharmacological
effect of mutations at the PAA receptor site in IVS6 of the
1 subunit in tsA201 cells. The combined mutation of
residues Tyr-1463, Ala-1467, and Ile-1470 reduced
use-dependent block and accelerated the rate of recovery
from inactivation. The result of their studies suggested that the
mutant YAI residues interact directly with verapamil and introduce
steric hindrance to drug access and binding.
Degtiar et al. (5, 31) showed that mutation I1811M
(AL25/-I) in transmembrane segment IVS6 had the highest impact,
reducing use dependence and displaying the slowest inactivation time
course. They suggested that this pore-lining isoleucine in IVS6 played a key role in the formation of the PAA receptor site. Berjukov et
al. (11) also reported that two amino acids from segment IVS6 in
rabbit heart
1C-a (V1504A, L1381I) are strong
inactivation determinants and showed that the reduced
use-dependent block of V1504A caused by a reduced
(+)-cis-diltiazem sensitivity and could be explained by an
allosteric modulation of the drug binding process.
Kraus et al. (26) investigated the contribution of
individual IIIS6 amino acid residues for diltiazem sensitivity by
employing alanine-scanning mutagenesis. Mutations of IIIS6 residues
Phe-1164 and Val-1165 slowed inactivation kinetics and accelerated the recovery from drug block and were found to be major determinants for
use-dependent diltiazem block. They proposed that the time course of recovery from channel block was critically determined by steric orientation of the receptor determinants in the pore region
(9). This study was supported by recent observations by Kraus et
al. (32) in familial hemiplegic migraine mutation, which
demonstrated that pore-forming residues valine and isoleucine play an
important role for P/Q-type Ca2+ channel
inactivation and can be responsible for neuronal instability in
patients with hemiplegic migraine mutation. Sokolov et al. (33) demonstrated that amino acid substitutions outside the putative
drug-binding region in the intracellular loop between domains I and II,
the use-dependent block, was also modulated block by
(
)-gallopamil. Later, they presented experimental evidence that
different
-subunit compositions of Cav1.2 affect the
channel inactivation kinetics and PAA sensitivity as well (33, 34). Higher sensitivity to PAA was also observed with Ca2+ as a
charge carrier (34). In the latter case, however, the slower recovery
from PAA-induced channel conformation and not the inactivation played a
significant role in the enhanced use dependence. We also identified
amino acid residues outside of the drug-binding domain, at the
cytoplasmic end of the putative IVS5
-helix, as important
determinants for the inactivation mechanism. Our results support the
notion that residues in IVS5 indirectly control diltiazem sensitivity
in a frequency-dependent manner by slowing channel
inactivation and by facilitating recovery from drug block and channel
unblock between individual test pulses of train.
In summary, a number of results provide evidence that more than one
region of the
1-subunit of the L-type Ca2+
channel contributes to use-dependent block by PAA and BTZ
drugs. These regions include the IVS6, IVS5, IIS6, and I-II
intracellular connecting loop and also the nature of the
-subunit
and the charge carrier involved. The common underlying mechanism of the
phenomenon is probably in the voltage-dependent
inactivation and inactivated conformation of the channel molecule. Thus
far, there is no information about the three-dimensional structure of
calcium channels. An increasing body of information, however, points to
the movement of the voltage sensor and associated membrane segments
(35, 36). Thus, it is conceivable that regions of the inactivated channel, including the PAA and BTZ "receptor pocket" that are otherwise buried in membrane, move out into the extracellular space and
provide better access to the drug. This process occurs regardless of
which mechanism has generated the accumulation of the inactive channel.
 |
FOOTNOTES |
*
This work was supported in part by National Institutes of
Health Grants POI HL22619 (to A. S.) and T32 HL07382 (to A. S.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
To whom correspondence should be addressed: Institute of Molecular
Pharmacology and Biophysics, University of Cincinnati College of
Medicine, Cardiovascular Research Center, G-933, P. O. Box 670828, 231 Albert Sabin Way, Cincinnati, OH 45267-0828. Tel.: 513-558-7047; Fax:
513-558-1778; Email: bodii@email.uc.edu.
Published, JBC Papers in Press, March 23, 2002, DOI 10.1074/jbc.M200752200
 |
ABBREVIATIONS |
The abbreviations used are:
DHP, dihydropyridines;
PAA, phenylalkylamines;
BTZ, benzothiazepines;
WT, wild type.
 |
REFERENCES |
| 1.
|
Weir, M. R.
(1995)
Cardiovasc. Res.
35,
220-232
|
| 2.
|
Klaus, D.
(1992)
J. Cardiovasc. Pharmacol.
20,
S5-S14
|
| 3.
|
Ferrari, R.
(1997)
Eur. Heart J.
18,
A56-A70
|
| 4.
|
Opie, L. H.
(1997)
Eur. Heart J.
18,
A71-A79
|
| 5.
|
Hering, S.,
Aczel, S.,
Grabner, M.,
Doring, F.,
Berjukov, S.,
Mitterdorfer, J.,
Striessnig, J.,
Degtiar, V. E.,
Wang, Z.,
and Glossmann, H.
(1996)
J. Biol. Chem.
271,
24471-24475[Abstract/Free Full Text]
|
| 6.
|
Sinneger, M. J.,
Wang, Z.,
Grabner, M.,
Hering, S.,
Glossmann, H.,
and Mitterdorfer, J.
(1997)
J. Biol. Chem.
272,
27686-27693[Abstract/Free Full Text]
|
| 7.
|
Hockermann, G. H.,
Peterson, B. Z.,
Sharp, E.,
Tanada, T.,
Schener, T.,
and Catterall, W. A.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
14906-14911[Abstract/Free Full Text]
|
| 8.
|
Bodi, I.,
Yamaguchi, H.,
Hara, M., He, M.,
Schwartz, A.,
and Varadi, G.
(1997)
J. Biol. Chem.
272,
24952-24960[Abstract/Free Full Text]
|
| 9.
|
Hering, S.,
Aczel, S.,
Kraus, R. L.,
Berjukov, S.,
Striessnig, J.,
and Timin, E. N.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
13323-13328[Abstract/Free Full Text]
|
| 10.
|
Peterson, B. Z.,
Johnson, B. D.,
Hockermann, G. H.,
Acheson, M. J.,
Scheuer, T.,
and Catterall, W. A.
(1997)
J. Biol. Chem.
272,
18752-18758[Abstract/Free Full Text]
|
| 11.
|
Berjukov, S.,
Gapp, F.,
Aczel, S.,
Sinnegger, M. J.,
Mitterdorfer, J.,
Glossmann, H.,
and Hering, S.
(1999)
J. Biol. Chem.
274,
6154-6160[Abstract/Free Full Text]
|
| 12.
|
Hering, S.,
Berjukov, S.,
Aczel, S.,
and Timin, E. N.
(1998)
Trends Pharmacol. Sci.
19,
439-443[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Motoike, H. K.,
Bodi, I.,
Nakayama, H.,
Schwartz, A.,
and Varadi, G.
(1999)
J. Biol. Chem.
274,
9409-9420[Abstract/Free Full Text]
|
| 14.
|
Schultz, D.,
Mikala, G.,
Yatani, A.,
Engle, D. B.,
Iles, D. E.,
Segers, B.,
Sinke, R. J.,
Weghuis, D. O.,
Klockner, U.,
Wakamori, M.,
Wang, J.,
Melvin, D.,
Varadi, G.,
and Schwartz, A.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
6228-6232[Abstract/Free Full Text]
|
| 15.
|
Klockner, U.,
Mikala, G.,
Varadi, M.,
Varadi, G.,
and Schwartz, A.
(1995)
J. Biol. Chem.
270,
17306-17310[Abstract/Free Full Text]
|
| 16.
|
Tang, S.,
Yatani, A.,
Bahinski, A.,
Mori, Y.,
and Schwartz, A.
(1993)
Neuron
11,
1013-1021[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Ellis, S. B.,
Williams, M. E.,
Ways, N. R.,
Brenner, R.,
Sharp, A. H.,
Leung, A. T.,
Campbell, K. P.,
McKenna, E.,
Koch, W. J.,
Hui, A.,
Schwartz, A.,
and Harpold, M. M.
(1988)
Science
241,
1661-1664[Abstract/Free Full Text]
|
| 18.
|
Collin, T.,
Lory, P.,
Taviaux, S.,
Courtieu, C.,
Guilbault, P.,
Berta, P.,
and Nargeot, J.
(1994)
Eur. J. Biochem.
220,
257-262[Medline]
[Order article via Infotrieve]
|
| 19.
|
Bezanilla, F.,
and Armstrong, C. M.
(1977)
J. Gen. Physiol.
70,
549-566[Abstract/Free Full Text]
|
| 20.
|
Yamaguchi, H.,
Muth, J. N.,
Varadi, M.,
Schwartz, A.,
and Varadi, G.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
1357-1362[Abstract/Free Full Text]
|
| 21.
|
Hess, P.,
Lansman, J. B.,
and Tsien, R. W.
(1984)
Nature
311,
538-544[CrossRef][Medline]
[Order article via Infotrieve]
|
| 22.
|
Wakamori, M.,
Mikala, G.,
Schwartz, A.,
and Yatani, A.
(1993)
Biochem. Biophys. Res. Commun.
196,
1170-1176[CrossRef][Medline]
[Order article via Infotrieve]
|
| 23.
|
Chahine, M.,
George, A. L., Jr.,
Zhou, M., Ji, S.,
Sun, W.,
Barchi, R. L.,
and Horn, R.
(1994)
Neuron
12,
281-294[CrossRef][Medline]
[Order article via Infotrieve]
|
| 24.
|
Deschenes, I.,
Trottier, E.,
and Chahine, M.
(1999)
Cardiovasc. Res.
42,
521-529[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Hockerman, G. H.,
Johnson, B. D.,
Abbott, M. R.,
Scheuer, T.,
and Catterall, W. A.
(1997)
J. Biol. Chem.
272,
18759-18765[Abstract/Free Full Text]
|
| 26.
|
Kraus, R. L.,
Hering, S.,
Grabner, M.,
Ostler, D.,
and Striessnig, J.
(1998)
J. Biol. Chem.
273,
27205-27212[Abstract/Free Full Text]
|
| 27.
|
McPhee, J. C.,
Ragsdale, D. S.,
Scheuer, T.,
and Catterall, W. A.
(1998)
J. Biol. Chem.
273,
1121-1129[Abstract/Free Full Text]
|
| 28.
|
West, J. W.,
Patton, D. E.,
Scheuer, T.,
Wang, Y.,
Goldin, A. L.,
and Catterall, W. A.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
10910-10914[Abstract/Free Full Text]
|
| 29.
|
Hockerman, G. H.,
Johnson, B. D.,
Scheuer, T.,
and Catterall, W. A.
(1995)
J. Biol. Chem.
270,
22119-22122[Abstract/Free Full Text]
|
| 30.
|
Johnson, B. D.,
Hockerman, G. H.,
Scheuer, T.,
and Catterall, W. A.
(1996)
Mol. Pharmacol.
50,
1388-1400[Abstract]
|
| 31.
|
Degtiar, V. E.,
Aczel, S.,
Doring, E. N.,
Timin, E. N.,
Berjukov, S.,
Kimball, D.,
Mitterdorfer, J.,
and Hering, S.
(1997)
Biophys. J.
73,
157-167[Abstract/Free Full Text]
|
| 32.
|
Kraus, R. L.,
Sinnegger, M. J.,
Glossmann, H.,
Hering, S.,
and Striessnig, J.
(1998)
J. Biol. Chem.
273,
5586-5590[Abstract/Free Full Text]
|
| 33.
|
Sokolov, S.,
Weiss, R. G.,
Kurka, B.,
Gapp, F.,
and Hering, S.
(1999)
J. Physiol. (Lond.)
515,
315-322[Abstract/Free Full Text]
|
| 34.
|
Sokolov, S.,
Timin, E.,
and Hering, S.
(2001)
Circ. Res.
89,
700-708[Abstract/Free Full Text]
|
| 35.
|
Glauner, K. S.,
Mannuzzu, L. M.,
Gandhi, C. S.,
and Isacoff, E. Y.
(1999)
Nature
402,
813-815[CrossRef][Medline]
[Order article via Infotrieve]
|
| 36.
|
Mannuzzu, L. M.,
Moronne, M. M.,
and Isacoff, E. Y.
(1996)
Science
271,
213-216[Abstract]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
O. Dafi, L. Berrou, Y. Dodier, A. Raybaud, R. Sauve, and L. Parent
Negatively Charged Residues in the N-terminal of the AID Helix Confer Slow Voltage Dependent Inactivation Gating to CaV1.2
Biophys. J.,
November 1, 2004;
87(5):
3181 - 3192.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Dilmac, N. Hilliard, and G. H. Hockerman
Molecular Determinants of Ca2+ Potentiation of Diltiazem Block and Ca2+-Dependent Inactivation in the Pore Region of Cav1.2
Mol. Pharmacol.,
August 1, 2003;
64(2):
491 - 501.
[Abstract]
[Full Text]
[PDF]
|
 |
|